Waldencast (WALD) to Release Earnings on Tuesday

Waldencast (NASDAQ:WALD - Get Free Report) is projected to release its earnings data after the market closes on Tuesday, March 18th. Analysts expect Waldencast to post earnings of ($0.07) per share and revenue of $70.43 million for the quarter. Parties that are interested in registering for the company's conference call can do so using this link.

Waldencast Trading Down 0.6 %

Shares of Waldencast stock traded down $0.02 during trading hours on Tuesday, hitting $3.10. The company's stock had a trading volume of 28,189 shares, compared to its average volume of 130,407. The company has a debt-to-equity ratio of 0.21, a quick ratio of 0.78 and a current ratio of 1.47. The firm has a fifty day moving average of $3.27 and a 200-day moving average of $3.47. Waldencast has a twelve month low of $2.41 and a twelve month high of $7.54.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on WALD. DA Davidson raised their target price on Waldencast from $7.25 to $7.50 and gave the stock a "buy" rating in a research report on Wednesday, December 4th. Canaccord Genuity Group lifted their target price on Waldencast from $5.00 to $6.00 and gave the company a "buy" rating in a research note on Friday, November 22nd. TD Cowen assumed coverage on shares of Waldencast in a research report on Monday, December 16th. They issued a "hold" rating and a $4.30 price objective for the company. Finally, Telsey Advisory Group restated an "outperform" rating and set a $6.00 target price on shares of Waldencast in a research report on Tuesday. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $5.76.

Remove Ads

Waldencast Company Profile

Waldencast plc operates in the beauty and wellness business. The company engages in developing, acquiring, accelerating, and scaling various brands. It provides cosmetic, over-the-counter, and prescription products under the Obagi Medical, Obagi Clinical, and Obagi Professional brands; and a Skintrinsiq device for use in facial treatments that is used by physicians' offices, spas, and aestheticians.